ADAGENE UNVEILS PRECLINICAL DATA AT 63RD AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

KUALA LUMPUR, Dec 14 (Bernama) -- Biopharmaceutical company, Adagene Inc (Adagene), has announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE).

The data were presented in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition taking place Dec 11-14, 2021 which are available in the Publications section of the company’s website, according to a statement.

“Our novel anti-CD47 antibody and CD20xCD3 bispecific TCE programs successfully leverage SAFEbody technology for precision masking to decouple efficacy from the toxicities that are often associated with therapeutic modalities for these two important targets on the forefront of clinical development for hematologic malignancies,” said Adagene Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D.

“Our preclinical evaluation shows the desirable target product profiles of these two transformative programs emerging from our deep, broad and differentiated pipeline.”

The poster (#3342) titled ‘ADG153, an Anti-CD-47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass’.

Key findings from the poster include given the dose-limiting hematologic toxicity and antigen sink liability associated with current anti-CD47 antibodies in clinical development, Adagene has developed an anti-CD47 SAFEbody with precision masking for preferential binding on CD47 overexpressed on tumour versus normal cells.

Meanwhile, the poster (#1204) titled ‘ADG152, a Novel CD20xCD3 T-Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety’.

Key findings from the poster include ADG152 is a bispecific CD20xCD3 T-cell engager POWERbody that integrates SAFEbody precision masking technology to minimise cytokine release syndrome (CRS) and on-target/off-tumour toxicities for an increased therapeutic index.

Both ADG153 and ADG152 are potential Investigational New Drug candidates from Adagene’s growing portfolio of preclinical discovery programs, five of which are in IND-enabling studies.

The preclinical data presented at ASH provide a strong rationale for advancing these potentially best-in-class candidates into clinical development.

More details at www.adagene.com.

-- BERNAMA